These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 26732592)
1. Dysregulation of ErbB Receptor Trafficking and Signaling in Demyelinating Charcot-Marie-Tooth Disease. Lee SM; Chin LS; Li L Mol Neurobiol; 2017 Jan; 54(1):87-100. PubMed ID: 26732592 [TBL] [Abstract][Full Text] [Related]
2. Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease. McLean JW; Wilson JA; Tian T; Watson JA; VanHart M; Bean AJ; Scherer SS; Crossman DK; Ubogu E; Wilson SM J Neurosci; 2022 Jun; 42(25):5085-5101. PubMed ID: 35589390 [TBL] [Abstract][Full Text] [Related]
4. Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease. Murakami T; Sunada Y Adv Exp Med Biol; 2019; 1190():301-321. PubMed ID: 31760652 [TBL] [Abstract][Full Text] [Related]
5. Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A. Park NY; Kwak G; Doo HM; Kim HJ; Jang SY; Lee YI; Choi BO; Hong YB Curr Issues Mol Biol; 2021 Nov; 43(3):2011-2021. PubMed ID: 34889893 [TBL] [Abstract][Full Text] [Related]
6. [Molecular genetics of inherited neuropathies]. Takashima H Rinsho Shinkeigaku; 2006 Jan; 46(1):1-18. PubMed ID: 16541790 [TBL] [Abstract][Full Text] [Related]
10. Aberrant Neuregulin 1/ErbB Signaling in Charcot-Marie-Tooth Type 4D Disease. Jiang LT; Chen YH; Huang JH; Tong WF; Jin LJ; Li LX Mol Cell Biol; 2022 Jul; 42(7):e0055921. PubMed ID: 35708320 [TBL] [Abstract][Full Text] [Related]
11. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559 [TBL] [Abstract][Full Text] [Related]
12. Genetic mechanisms of peripheral nerve disease. Stavrou M; Sargiannidou I; Christofi T; Kleopa KA Neurosci Lett; 2021 Jan; 742():135357. PubMed ID: 33249104 [TBL] [Abstract][Full Text] [Related]
13. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. Schiza N; Georgiou E; Kagiava A; Médard JJ; Richter J; Tryfonos C; Sargiannidou I; Heslegrave AJ; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Chrast R; Kleopa KA Brain; 2019 May; 142(5):1227-1241. PubMed ID: 30907403 [TBL] [Abstract][Full Text] [Related]
14. Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model. Scapin C; Ferri C; Pettinato E; Zambroni D; Bianchi F; Del Carro U; Belin S; Caruso D; Mitro N; Pellegatta M; Taveggia C; Schwab MH; Nave KA; Feltri ML; Wrabetz L; D'Antonio M Hum Mol Genet; 2019 Mar; 28(6):992-1006. PubMed ID: 30481294 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms for Charcot-Marie-Tooth disease and related demyelinating peripheral neuropathies. Warner LE; Reiter LT; Murakami T; Lupski JR Cold Spring Harb Symp Quant Biol; 1996; 61():659-71. PubMed ID: 9246492 [No Abstract] [Full Text] [Related]
20. Exclusive expression of the Rab11 effector SH3TC2 in Schwann cells links integrin-α6 and myelin maintenance to Charcot-Marie-Tooth disease type 4C. Vijay S; Chiu M; Dacks JB; Roberts RC Biochim Biophys Acta; 2016 Jul; 1862(7):1279-90. PubMed ID: 27068304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]